David Lagares

Dr. Lagares’s research interests focus on tissue repair, regeneration and fibrosis. His research laboratory concentrates on understanding the fundamental mechanisms that balance tissue regeneration and fibrosis following injury. Ultimately, his laboratory seeks to develop novel anti-fibrotic therapies aimed at reducing tissue fibrosis and promoting the regeneration of damaged organs for the treatment of human fibrotic diseases such as idiopathic pulmonary fibrosis, systemic sclerosis, liver cirrhosis, progressive kidney disease and desmoplastic tumors. Dr. Lagares has made multiple seminal contributions to this field including the identification of the ADAM10-sEphrin-B2 pathway in lung injury and fibrosis and the use of BH3 mimetic drugs to induce myofibroblast apoptosis and reversion of established fibrosis. Dr. Lagares’s laboratory is affiliated with the Division of Pulmonary and Critical Care Medicine at the Massachusetts General Hospital (MGH). He is also a Principal Investigator at Center for Immunology and Inflammatory Diseases (CIID) and serves as the Director of the Matrix and Mechanobiology Program at the MGH Fibrosis Research Center.

Awards and Recognition

Dr. Lagares’s has received numerous awards and honors, including The Marie Coyle Research Grant awarded by the Scleroderma Foundation (2015), the ATS Foundation/Pulmonary Fibrosis Foundation Research Grant (2016) and the Scleroderma Research Foundation Grant (2017). His research work has been recognized and awarded at the national and international level in multiple scientific meetings including the American Thoracic Society International Conference, the International Colloquium On Lung And Airway Fibrosis, the Keystone Symposia Conference or the Japan College of Rheumatology International Conference. Dr. Lagares serves as Ad hoc Reviewer for the study section of The Medical Research Council (United Kingdom), The Health Research Board (Ireland), The National Plan for Spanish Research and Development Board (Spain) and The Agency for Medical Research and Development (Japan), and as a reviewer for many high profile peer-review scientific journals, including Nature Medicine, The Journal of Clinical Investigation, American Journal of Respiratory Cell and Molecular Biology and Arthritis & Rheumatism.